Standout Papers

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis 2024 202631
  1. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis (2024)
    James F. Howard, Vera Bril et al. Frontiers in Neurology

Immediate Impact

9 standout
Sub-graph 1 of 5

Citing Papers

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease
2024 Standout
2 intermediate papers

Works of Chafic Karam being referenced

Nusinersen in adult patients with spinal muscular atrophy
2020
CMT AND NEUROGENIC DISEASE
2018

Author Peers

Author Last Decade Papers Cites
Chafic Karam 108 30 37 61 44 21 184
Perrine Devic 126 21 26 28 34 16 270
Michael Gelsomino 84 12 36 87 57 28 251
Marta Lipowska 138 25 30 34 53 23 236
Victor Hugo Rocha Marussi 81 21 11 68 43 26 204
Imaduddin Kanaan 64 30 51 80 39 17 270
Lars Hendrik Müschen 125 14 35 102 74 13 291
Fiammetta Vanoli 169 46 22 53 105 29 279
Ge Jia 99 11 63 97 65 22 287
Alessandro Beronio 136 11 21 28 22 18 231
Rita Figueiredo 43 9 24 41 43 20 195

All Works

Loading papers...

Rankless by CCL
2026